PRDM10肾细胞癌:一种与脂肪瘤及高外显、侵袭性、形态似2型乳头状肾细胞癌相关的Birt-Hogg-Dubé样综合征
该研究对具有脂肪瘤及Birt-Hogg-Dubé样表现(包括纤维毛囊瘤、毛盘瘤和肾癌)的患者家族进行基因组分析,发现PRDM10胚系致病性变异(c.2029T>C,p.Cys677Arg)与疾病共分离,肾肿瘤中可见PRDM10杂合性缺失及GPNMB表达升高,提示PRDM10改变导致FLCN表达降低。作者认为,对无FLCN胚系致病变异但具有Birt-Hogg-Dubé样表现和皮下脂肪瘤的个体应筛查PRDM10胚系变异,PRDM10致病变异患者的肾脏肿瘤应手术切除而非主动监测。
要点
- PRDM10胚系致病变异(c.2029T>C,p.Cys677Arg)与脂肪瘤、纤维毛囊瘤/毛盘瘤及高外显侵袭性家族性乳头状肾细胞癌共分离。
- 肾肿瘤中检出PRDM10杂合性缺失和GPNMB表达升高,提示PRDM10改变导致FLCN表达降低并驱动TFE3相关肿瘤形成。
- 作者建议无FLCN胚系致病变异但有Birt-Hogg-Dubé样表现和皮下脂肪瘤者筛查PRDM10胚系变异,PRDM10致病变异者的肾肿瘤应手术切除而非主动监测。
核心结论
- 研究识别出PRDM10胚系致病变异与高外显、侵袭性家族性乳头状肾细胞癌、脂肪瘤及纤维毛囊瘤/毛盘瘤相关。
- 肾肿瘤中PRDM10杂合性缺失和GPNMB表达升高提示PRDM10改变导致FLCN表达降低,驱动TFE3诱导的肿瘤形成。
- 作者认为,无FLCN胚系致病变异但有Birt-Hogg-Dubé样表现和皮下脂肪瘤的个体应筛查PRDM10胚系变异。
- 作者认为,PRDM10致病变异患者的肾脏肿瘤应手术切除而非主动监测。
研究设计与样本
- 研究对患者血液和肾肿瘤DNA进行基因组分析,记录遗传模式、表型表现及临床和手术管理,并表征皮肤、皮下和肾肿瘤病理特征。
- 全基因组测序鉴定出PRDM10胚系致病性变异(c.2029 T>C,p.Cys677Arg),该变异与疾病共分离。
主要发现
- 受累个体存在高外显且致命性的双侧、多灶性乳头状肾细胞癌风险。
- 肾肿瘤中检出PRDM10杂合性缺失。
- PRDM10被预测可消除FLCN表达,而FLCN是PRDM10的转录靶点;肿瘤中GPNMB表达证实了FLCN缺失,GPNMB是TFE3/TFEB靶点及FLCN缺失的下游生物标志物。
- TCGA队列中一例散发性乳头状肾细胞癌被检出体细胞PRDM10突变。
临床怎么用
- 作者认为,具有Birt-Hogg-Dubé样表现和皮下脂肪瘤但无FLCN胚系致病变异的个体应筛查PRDM10胚系变异。
- 作者认为,PRDM10致病变异患者的肾脏肿瘤应手术切除而非主动监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To characterize the clinical manifestations and genetic basis of a familial cancer syndrome in patients with lipomas and Birt-Hogg-Dubé-like clinical manifestations including fibrofolliculomas and trichodiscomas and kidney cancer. METHODS: Genomic analysis of blood and renal tumor DNA was performed. Inheritance pattern, phenotypic manifestations, and clinical and surgical management were documented. Cutaneous, subcutaneous, and renal tumor pathologic features were characterized. RESULTS: Affected individuals were found to be at risk for a highly penetrant and lethal form of bilateral, multifocal papillary renal cell carcinoma. Whole genome sequencing identified a germline pathogenic variant in PRDM10 (c.2029 T>C, p.Cys677Arg), which cosegregated with disease. PRDM10 loss of heterozygosity was identified in kidney tumors. PRDM10 was predicted to abrogate expression of FLCN, a transcriptional target of PRDM10, which was confirmed by tumor expression of GPNMB, a TFE3/TFEB target and downstream biomarker of FLCN loss. In addition, a sporadic papillary RCC from the TCGA cohort was identified with a somatic PRDM10 mutation. CONCLUSION: We identified a germline PRDM10 pathogenic variant in association with a highly penetrant, aggressive form of familial papillary RCC, lipomas, and fibrofolliculomas/trichodiscomas. PRDM10 loss of heterozygosity and elevated GPNMB expression in renal tumors indicate that PRDM10 alteration leads to reduced FLCN expression, driving TFE3-induced tumor formation. These findings suggest that individuals with Birt-Hogg-Dubé-like manifestations and subcutaneous lipomas, but without a germline pathogenic FLCN variant, should be screened for germline PRDM10 variants. Importantly, kidney tumors identified in patients with a pathogenic PRDM10 variant should be managed with surgical resection instead of active surveillance.
引用
- Schmidt LS, Vocke CD, Ricketts CJ, et al. PRDM10 RCC: A Birt-Hogg-Dubé-like Syndrome Associated With Lipoma and Highly Penetrant, Aggressive Renal Tumors Morphologically Resembling Type 2 Papillary Renal Cell Carcinoma. Urology. 2023. PMID: 37331486. doi:10.1016/j.urology.2023.04.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。